← Leaderboards
Kai Fu
Roswell Park Cancer Institute Corp
$831,328
Attributed
$831,328
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $381.4K · FY2021–23$500K$375K$250K$125K$0
'21
'22
'23
Funding mix
By agency
NIH$831,328 · 2
By mechanism
P30$416,080 · 1
R21$415,248 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Scott I. Abrams$11,133,748
- Sharon S Evans$8,115,501
- Li Tang$8,006,573
- Craig M. Brackett$2,746,152
- Xuefang Cao$8,586,764
Others in their field
Other Emerging Leaders on “Future”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- John E West · University Of Texas At Austin$128,483,161
- Beth Baseler · Leidos Biomedical Research, Inc.$117,364,154
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
Research focus
FutureResearch PersonnelReportingMultiple MyelomaBaseCellsCollaborationsRegulationAnti-CancerAffectAntigen-Specific T CellsAnticancer ResearchAreaAwardAdvisory CommitteesActive SitesAdoptedB-LymphocytesBiological MarkersAnalytical Tool5&AposCancer CellCancer Center Support GrantBinding
Grant awards (4)
Flow & Image Cytometry Shared Resource$202,775
P30 · FY2023 · CA · contact PI
Flow & Image Cytometry Shared Resource$213,305
P30 · FY2022 · CA · contact PI
Synthetic rocaglates as promising therapeutic agents for aggressive hematological malignancies$168,113
R21 · FY2022 · CA · contact PI
Synthetic rocaglates as promising therapeutic agents for aggressive hematological malignancies$247,135
R21 · FY2021 · CA · contact PI